Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

janssen-cilag ab - epoetin alfa - injektionsvätska, lösning - 2000 ie/ml - epoetin alfa 2000 ie aktiv substans - erytropoietin

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

janssen-cilag ab - epoetin alfa - injektionsvätska, lösning - 40 000 ie/ml - epoetin alfa 40 kie aktiv substans - erytropoietin

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

orifarm ab - epoetin alfa - injektionsvätska, lösning - 40 000 ie/ml - epoetin alfa 40 kie aktiv substans - erytropoietin

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

janssen-cilag ab - epoetin alfa - injektionsvätska, lösning - 4000 ie/ml - epoetin alfa 4000 ie aktiv substans - erytropoietin

Euroopa Liit - rootsi - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemiska preparat - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Euroopa Liit - rootsi - EMA (European Medicines Agency)

astellas pharma europe b.v. - roxadustat - anemia; kidney failure, chronic - antianemiska preparat - evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (ckd).

Euroopa Liit - rootsi - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - andra preparat antianemic - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Rootsi - rootsi - Läkemedelsverket (Medical Products Agency)

hexal a/s - pemetrexeddinatrium-2,5-hydrat - koncentrat till infusionsvätska, lösning - 25 mg/ml - pemetrexeddinatrium-2,5-hydrat 30,2 mg aktiv substans; propylenglykol hjälpämne